vs
Arcellx, Inc.（ACLX）与ADMA BIOLOGICS, INC.（ADMA）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Arcellx, Inc.的84.1倍（$139.2M vs $1.7M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs -3513.4%，领先3548.9%）。ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -89.2%）。ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-58.9M）。过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
ACLX vs ADMA — 直观对比
营收规模更大
ADMA
是对方的84.1倍
$1.7M
营收增速更快
ADMA
高出107.6%
-89.2%
净利率更高
ADMA
高出3548.9%
-3513.4%
自由现金流更多
ADMA
多$93.5M
$-58.9M
两年增速更快
ADMA
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $139.2M |
| 净利润 | $-58.1M | $49.4M |
| 毛利率 | — | 63.8% |
| 营业利润率 | -3850.2% | 45.1% |
| 净利率 | -3513.4% | 35.5% |
| 营收同比 | -89.2% | 18.4% |
| 净利润同比 | -23.4% | -55.9% |
| 每股收益（稀释后） | $-1.01 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXADMA
| Q4 25 | $1.7M | $139.2M | ||
| Q3 25 | $4.9M | $134.2M | ||
| Q2 25 | $7.6M | $122.0M | ||
| Q1 25 | $8.1M | $114.8M | ||
| Q4 24 | $15.3M | $117.5M | ||
| Q3 24 | $26.0M | $119.8M | ||
| Q2 24 | $27.4M | $107.2M | ||
| Q1 24 | $39.3M | $81.9M |
净利润ACLXADMA
| Q4 25 | $-58.1M | $49.4M | ||
| Q3 25 | $-55.8M | $36.4M | ||
| Q2 25 | $-52.8M | $34.2M | ||
| Q1 25 | $-62.3M | $26.9M | ||
| Q4 24 | $-47.1M | $111.9M | ||
| Q3 24 | $-25.9M | $35.9M | ||
| Q2 24 | $-27.2M | $32.1M | ||
| Q1 24 | $-7.2M | $17.8M |
毛利率ACLXADMA
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 56.3% | ||
| Q2 25 | — | 55.1% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 53.9% | ||
| Q3 24 | — | 49.8% | ||
| Q2 24 | — | 53.6% | ||
| Q1 24 | — | 47.8% |
营业利润率ACLXADMA
| Q4 25 | -3850.2% | 45.1% | ||
| Q3 25 | -1248.3% | 38.0% | ||
| Q2 25 | -777.4% | 35.1% | ||
| Q1 25 | -847.6% | 30.4% | ||
| Q4 24 | -348.2% | 32.6% | ||
| Q3 24 | -129.1% | 33.1% | ||
| Q2 24 | -127.8% | 36.6% | ||
| Q1 24 | -40.3% | 26.7% |
净利率ACLXADMA
| Q4 25 | -3513.4% | 35.5% | ||
| Q3 25 | -1127.1% | 27.1% | ||
| Q2 25 | -698.6% | 28.1% | ||
| Q1 25 | -766.0% | 23.4% | ||
| Q4 24 | -308.4% | 95.2% | ||
| Q3 24 | -99.4% | 30.0% | ||
| Q2 24 | -99.3% | 29.9% | ||
| Q1 24 | -18.3% | 21.7% |
每股收益（稀释后）ACLXADMA
| Q4 25 | $-1.01 | $0.20 | ||
| Q3 25 | $-0.99 | $0.15 | ||
| Q2 25 | $-0.94 | $0.14 | ||
| Q1 25 | $-1.13 | $0.11 | ||
| Q4 24 | $-0.87 | $0.45 | ||
| Q3 24 | $-0.48 | $0.15 | ||
| Q2 24 | $-0.51 | $0.13 | ||
| Q1 24 | $-0.14 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $87.6M |
| 总债务越低越好 | — | $72.1M |
| 股东权益账面价值 | $402.4M | $477.3M |
| 总资产 | $604.0M | $624.2M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资ACLXADMA
| Q4 25 | $450.3M | $87.6M | ||
| Q3 25 | $461.4M | $61.4M | ||
| Q2 25 | $453.1M | $90.3M | ||
| Q1 25 | $543.3M | $71.6M | ||
| Q4 24 | $587.4M | $103.1M | ||
| Q3 24 | $574.3M | $86.7M | ||
| Q2 24 | $516.7M | $88.2M | ||
| Q1 24 | $573.9M | $45.3M |
总债务ACLXADMA
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACLXADMA
| Q4 25 | $402.4M | $477.3M | ||
| Q3 25 | $440.8M | $431.2M | ||
| Q2 25 | $392.2M | $398.3M | ||
| Q1 25 | $416.9M | $373.4M | ||
| Q4 24 | $454.8M | $349.0M | ||
| Q3 24 | $483.0M | $231.9M | ||
| Q2 24 | $487.2M | $188.3M | ||
| Q1 24 | $496.6M | $153.7M |
总资产ACLXADMA
| Q4 25 | $604.0M | $624.2M | ||
| Q3 25 | $655.9M | $568.7M | ||
| Q2 25 | $619.1M | $558.4M | ||
| Q1 25 | $648.1M | $510.6M | ||
| Q4 24 | $711.3M | $488.7M | ||
| Q3 24 | $764.9M | $390.6M | ||
| Q2 24 | $734.3M | $376.4M | ||
| Q1 24 | $779.7M | $350.9M |
负债/权益比ACLXADMA
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $35.6M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $34.6M |
| 自由现金流率自由现金流/营收 | -3563.4% | 24.8% |
| 资本支出强度资本支出/营收 | 46.2% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.72× |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $27.8M |
8季度趋势，按日历期对齐
经营现金流ACLXADMA
| Q4 25 | $-58.2M | $35.6M | ||
| Q3 25 | $-49.2M | $13.3M | ||
| Q2 25 | $-39.7M | $21.1M | ||
| Q1 25 | $-63.1M | $-19.7M | ||
| Q4 24 | $-46.0M | $50.2M | ||
| Q3 24 | $30.7M | $25.0M | ||
| Q2 24 | $-36.2M | $45.6M | ||
| Q1 24 | $-31.9M | $-2.2M |
自由现金流ACLXADMA
| Q4 25 | $-58.9M | $34.6M | ||
| Q3 25 | $-49.5M | $-1.1M | ||
| Q2 25 | $-40.2M | $18.7M | ||
| Q1 25 | $-63.9M | $-24.4M | ||
| Q4 24 | $-47.5M | $47.5M | ||
| Q3 24 | $28.4M | $24.0M | ||
| Q2 24 | $-39.5M | $43.6M | ||
| Q1 24 | $-38.3M | $-4.6M |
自由现金流率ACLXADMA
| Q4 25 | -3563.4% | 24.8% | ||
| Q3 25 | -1000.3% | -0.8% | ||
| Q2 25 | -532.4% | 15.3% | ||
| Q1 25 | -786.4% | -21.2% | ||
| Q4 24 | -311.3% | 40.4% | ||
| Q3 24 | 109.2% | 20.0% | ||
| Q2 24 | -144.1% | 40.7% | ||
| Q1 24 | -97.7% | -5.6% |
资本支出强度ACLXADMA
| Q4 25 | 46.2% | 0.8% | ||
| Q3 25 | 6.0% | 10.7% | ||
| Q2 25 | 6.4% | 2.0% | ||
| Q1 25 | 9.6% | 4.1% | ||
| Q4 24 | 9.8% | 2.3% | ||
| Q3 24 | 8.8% | 0.9% | ||
| Q2 24 | 11.7% | 1.9% | ||
| Q1 24 | 16.4% | 2.9% |
现金转化率ACLXADMA
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | -0.73× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | -0.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
